Clinical trials: Pancreas Cancer, open to volunteers
Diabetes Mellitus, Pancreatic Cancer, Adult
Surveillance of Pancreatic Health After Diabetes Diagnosis
The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes or with elevated sugar levels within the last…
- Trial name
- SAFE-D (NCT06803771)
- Testing
- Avantect Pancreatic Cancer Test
- Where
- 31 sites in United Kingdom
- Volunteers
- 5,000 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Pancreatic Cancer
Role of Exosomes in Pancreatic Cancer Progression
The present pilot study is set up with the objective of identifying circulating markers in the biological fluids (blood and urine) of subjects with pancreatic carcinoma and their association with disease stage, to evaluate their…
- Trial name
- NCT06777030
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC)
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
This is a Phase 1, first-in-human (FIH), open-label, multicenter study designed to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of SHY-ONC6 in participants with advanced or metastatic solid tumors…
- Conditions
- Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer
- Trial name
- Luca-1 (NCT07705334)
- Testing
- SHY-ONC6
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- SHY Therapeutics
Advanced Malignancies, Oncology
Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies
Phase 1/2a Study of RP-001 in participants with Advanced Malignancies
- Conditions
- Advanced Malignancies, Oncology, Colorectal Cancer, Pancreatic Cancer
- Trial name
- NCT07504263
- Testing
- RP-001
- Volunteers
- 66 people
- Sponsor
- Recurv Pharma Inc
Colorectal Cancer, Pancreatic Cancer
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
The overall goal of this feasibility study is to assess the initial safety and efficacy of LUM015 in ex vivo far-red imaging of colorectal, pancreatic, and esophageal cancers (adenocarcinoma) using the LUM Imaging System.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT02584244
- Testing
- LUM015, LUM 2.6 Imaging Device
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Lumicell, Inc.
KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally, alone or in combination with other anticancer agents, to adults with advanced or metastatic solid tumors…
- Conditions
- KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant Colorectal Cancer (CRC), Other KRAS-mutant Solid Tumors
- Trial name
- NCT07458347
- Testing
- KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab
- Where
- 9 sites in United States
- Volunteers
- 545 people
- Sponsor
- Kestrel Therapeutics, Inc.
Pancreatic Cancer
A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer
This is a single-center, single-arm, open investigator-initiated clinical study to evaluate the efficacy and safety of VRT106 in combination with chemotherapy in the treatment of resectable pancreatic cancer.
- Trial name
- NCT06758544
- Testing
- Oncolytic virus VRT106, Chemotherapy
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Guangdong Provincial People's Hospital
Pancreatic Cancer
Irinotecan Liposome in Combination With Capecitabine
Pancreatic cancer is a group of malignant tumors mainly originated from pancreatic ductal epithelium and follicular cells, with high degree of malignancy, insidious onset, difficult early diagnosis, rapid progression, short…
- Trial name
- NCT06578052
- Testing
- Irinotecan liposome Capecitabine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Junjie Hang
Abdomen Cancer, Pancreas Adenocarcinoma (MSI-H)
Implementation of a Pain Management Plan in Major Open Abdominal Surgeries.
Introduction: Major abdominal surgery encompasses a broad range of surgical procedures in heterogeneous patient populations.Management of postoperative pain has received keen attention in recent years with considerable concurrent…
- Conditions
- Abdomen Cancer, Pancreas Adenocarcinoma (MSI-H), Colectomy Left/Right/Total Under Laparotomy, Hepatectomy
- Trial name
- NCT07901582
- Testing
- Epidural administered opioid
- Where
- Greece
- Volunteers
- 58 people
- Sponsor
- National and Kapodistrian University of Athens
Pancreatic Cancer
IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
This study is a multicenter, open-label, single-arm, phase Ib/II clinical study comprising two phases: dose confirmation phase and dose expansion phase.
- Trial name
- NCT05827796
- Testing
- IN10018, Albumin-Bound Paclitaxel, Gemcitabine
- Where
- China
- Volunteers
- 70 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Advanced Solid Cancers
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how severe they are.
- Trial name
- NCT07186842
- Testing
- BNT329, CA19-9-targeting monoclonal antibody
- Where
- 18 sites in United States, Australia and 3 more
- Volunteers
- 245 people
- Sponsor
- BioNTech SE
Pancreas Cancer, Non-Resectable Pancreas Carcinoma
Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer
The aim of the study is to compare the efficacy and toxicity of full-dose Gemcitabine and reduced-dose combination chemotherapy in patients with non-resectable pancreatic cancer, who are unfit for full-dose combination…
- Trial name
- NCT05841420
- Testing
- Gemcitabine, Nab paclitaxel
- Where
- Denmark
- Volunteers
- 98 people
- Sponsor
- Morten Ladekarl
Unresectable Pancreatic Cancer, Unresectable Bile Duct Carcinoma
Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers
Clinical trial phase: Phase 2 Intervention model: Control group Group allocation: Randomized controlled trial Research perspective: Prospective study Participating centers: Multicenter study Definition of the intervention period…
- Conditions
- Unresectable Pancreatic Cancer, Unresectable Bile Duct Carcinoma, Unresectable Biliary Tract Carcinoma
- Trial name
- Dulastin (NCT06135896)
- Testing
- Tripegfilgrastim
- Where
- South Korea
- Volunteers
- 98 people
- Sponsor
- National Cancer Center, Korea
Pancreatic Neuroendocrine Neoplasm
Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms
The phase II study is performed to assess the efficacy and safety of Nimotuzumab in patients with stage IV pancreatic neuroendocrine neoplasms and EGFR overexpression.
- Trial name
- NCT05316480
- Testing
- Nimotuzumab
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Fudan University
Pancreatic Ductal Adenocarcinoma
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
The goal of this clinical study is to compare the efficacy and safety of OT-101 in combination with mFOLFIRINOX (folinic acid, 5-FU, irinotecan, oxaliplatin) to mFOLFIRINOX alone in patients with advanced and unresectable or…
- Trial name
- STOP-PC (NCT06079346)
- Testing
- OT-101, mFOLFIRINOX
- Where
- 2 sites in United States
- Volunteers
- 455 people
- Sponsor
- Oncotelic Inc.
Intraductal Papillary Mucinous Neoplasm of Pancreas, Pancreatic Neoplasms
Real-Time AI During Pancreatoscopy for Detection of Pancreatic Neoplasia
This prospective pilot study will evaluate the diagnostic performance of a previously validated artificial intelligence (AI) model when applied in real time during digital per-oral pancreatoscopy (POPS).
- Trial name
- NCT07809841
- Testing
- AIWorks-Cholangioscopy Real-Time Artificial Intelligence Model
- Where
- Ecuador
- Volunteers
- 60 people
- Sponsor
- Instituto Ecuatoriano de Enfermedades Digestivas
Pancreatic Adenocarcinoma
QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC
This is a single-center, open-label, exploratory study to evaluate the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine as first-line treatment in patients with unresectable locally advanced or metastatic…
- Trial name
- NCT06750861
- Testing
- QL1706
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Locally Advanced Pancreatic Adenocarcinoma
Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy
A randomized controlled trial comparing the effect of local ablative MR-guided radiotherapy (MRgRT) after systemic therapy with current standard treatment alone, on health-related quality of life in patients with locally advanced…
- Trial name
- LAPSTAR (NCT06272162)
- Testing
- MR guided radiotherapy
- Where
- 4 sites in Netherlands
- Volunteers
- 150 people
- Sponsor
- UMC Utrecht
Epithelial Tumors, Malignant
Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors
MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial cancer.
- Trial name
- MYE Symphony (NCT05969041)
- Testing
- MT-302 (A)
- Where
- 6 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Myeloid Therapeutics
Gastric Cancer, Gastroesophageal Junction Cancer
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06219941
- Testing
- AZD0901, 5-Fluorouracil, Leucovorin
- Where
- 52 sites in United States, Australia and 12 more
- Volunteers
- 226 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.